HWM
ACAD icon

Hemington Wealth Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Hemington Wealth Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$2K Buy
122
+68
+126% +$1.61K ﹤0.01% 1302
2025
Q2 		$1K Buy
+54
New +$1K ﹤0.01% 1375

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Hemington Wealth Management's ACAD Position: Q3 2025 in Review

Hemington Wealth Management increased its Acadia Pharmaceuticals (ACAD) stake by 126% in Q3 2025, buying an estimated $1.61K and bringing the position to 122 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1302.

Hemington Wealth Management first reported a position in ACAD in Q2 2025 and has held it in 2 quarters since. 333 funds tracked by Wall St. Rank hold ACAD as of Q3 2025.

  • Hemington Wealth Management held 122 shares of Acadia Pharmaceuticals worth $2K as of Q3 2025.
  • Hemington Wealth Management bought 68 Acadia Pharmaceuticals shares in Q3 2025, an estimated $1.61K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Hemington Wealth Management's portfolio in Q3 2025, its #1302 holding.
  • Hemington Wealth Management first reported a position in Acadia Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • 333 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2025.

Based on Hemington Wealth Management's 13F filing for Q3 2025, filed 24 Oct 2025.